Piper Sandler Companies has appointed five new co-heads across its healthcare investment banking, consumer investment banking and equity capital markets groups, reflecting the firm’s strategic push to scale its advisory platform. Brandon Rice and Chad Huber join Peter Day as co-heads of healthcare investment banking; Rice brings extensive experience in M&A advisory and capital markets for disruptive medical technology firms, while Huber deepens the group’s life sciences equity origination capabilities. In the consumer team, Carlos Sanchez is elevated to co-head alongside incumbents Damon Chandik and Janica Lane, leveraging his track record in consumer M&A across diverse verticals. In equity capital markets, Paul Scansaroli is named global co-head with David Stadinski, expanding the group’s coverage of growth healthcare companies and their institutional backers. Leadership cohort statements emphasize deepening client relationships and driving the next phase of growth as transaction volumes in both M&A and equity issuance remain elevated year-to-date.

Piper Sandler’s advisory and corporate financing divisions are benefiting from a resurgence in biotech funding, robust mid-market private equity activity and a steady expansion of IPO markets supported by strong equity valuations. Equity issuance for life sciences clients has climbed by more than 35 percent compared with the prior year, while debt capital markets revenues remain solid despite modestly higher borrowing costs. The firm’s forward P/E multiple stands at 22 times consensus earnings, offering a valuation discount to key peers trading at 26 times, and an advantage over certain competitors below 20 times but with more limited growth prospects. Management highlights that M&A advisory fees are on track to exceed last year’s total by double-digit percentages, driven by cross-border deals and consolidation in high-growth therapeutic areas.